Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 146 Show results per page	View Search Criteria \| Help With Results


1.		Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				12 to 55				Pharmaceutical / Industry				GC P#02.01.001 NCT00469729


2.		In-Vivo Activated T-Cell Depletion to Prevent GVHD

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Active				18 to 75				Other				0705-20 IUCRO-0196 NCT00594308

Last Modified: 8/6/2008 First Published: 2/16/2007


3.		Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Matched-Sibling Donor Peripheral Blood Stem Cell Transplantation Versus G-CSF-Stimulated Matched-Sibling Donor Bone Marrow Transplantation in Patients With Hematologic Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 to 65				NCI				CBMTG-0601 NCT00438958

Last Modified: 5/23/2007


4.		Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Not specified				Other				MSKCC-95024 NCI-V95-0685, NCT00002663

Last Modified: 1/29/2008 First Published: 10/21/2005


5.		Phase I/II Study of Nonmyeloablative Conditioning Comprising Busulfan, Fludarabine, and Total-Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 75				NCI				OHSU-HEM-05011-L OHSU-210, NCT00245037


6.		Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 65				Other				03-0349 NCT00241358


7.		A Study of SB-743921 in Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				CY 2121 NCT00343564


8.		Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				06-065 X05175, NCT00369226


9.		Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				04U.115 NCT00429416

Last Modified: 6/28/2007 First Published: 5/21/2007


10.		Phase I/II Study of Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine in Patients Who Have Completed First-Line Therapy for Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				JHOC-J06143 J06143, JHOC-NA_00007920, NCT00478062

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute